Best Alzheimer's and Dementia Research Grants in Arizona

BrightFocus Foundation offers Alzheimer's Disease Research Grants to support innovative research aimed at understanding, preventing, and treating Alzheimer's disease. These grants encourage applications from diverse backgrounds, fostering creativity in scientific research. The program includes Standard Awards for early investigators with a maximum funding of $300,000 for three years and Postdoctoral Fellowship Awards for young researchers at $200,000 for two years, promoting the development of independent research careers.

The JTMF Foundation Grant focuses on improving the lives of individuals in need, particularly in the Pacific Northwest. By partnering with organizations addressing immediate needs and long-term challenges, the foundation supports children, older adults, veterans, and individuals with intellectual and developmental disabilities. Guided by Catholic values, JTMF aims to empower communities while seeking innovative solutions to societal issues. Organizations that align with these focus areas are encouraged to connect, fostering a collaborative effort towards meaningful impact.

The Alzheimer’s Foundation of America Bi-Annual Grant aims to support nonprofit organizations in their efforts to enhance the lives of individuals impacted by Alzheimer’s disease and related dementias. Each grant, valued at $6,000, is awarded twice a year, focusing on innovative programs and services. AFA emphasizes partnership and collaboration, enabling grantees to manage their own policies and programs while adhering to specific funding guidelines. This initiative underscores AFA's commitment to compassionate care and ethical standards.

The NIA Expanding Research in AD/ADRD Postbaccalaureate Research Education Program aims to enhance the research workforce by providing intensive research experiences for recent graduates. This initiative supports early-stage investigators in Alzheimer's Disease and related dementias, addressing a critical shortage of researchers in the field. Participants engage in independent research, mentorship, and professional development, equipping them with skills necessary for advanced degrees and research careers in aging and dementia. The program fosters innovation and interdisciplinary collaboration essential for advancing AD/ADRD research.

The NIA Expanding Research in AD/ADRD Summer Research Education Program supports the recruitment of early-stage investigators and aims to provide hands-on research experiences in Alzheimer's Disease and related dementias. Targeting high school students, undergraduates, and science teachers, the program enhances STEM education through authentic research opportunities and educational activities. By fostering early exposure to research, it aims to stimulate interest in AD/ADRD careers and address workforce shortages in this critical field.

The Alzheimer’s Association Research Grant For All (AARGA) Program supports early-career investigators in their first seven years as independent researchers. This grant aims to fund projects that develop preliminary data and test new hypotheses in Alzheimer’s and related dementia research. Areas of interest include disease mechanisms, biomarker development, and health equity. Applications are welcome from both U.S. and international researchers, fostering innovation and collaboration in the fight against dementia.

The Dementia Care and Brain Degenerative Diseases Grant, offered by the Sephardic Home For The Aged Foundation, aims to support innovative projects enhancing care and quality of life for older adults affected by dementia. Eligible organizations must be 501(c)3 nonprofits in operation for at least two years. The Foundation prioritizes proposals focusing on dementia care, promoting collaboration and resource access for aging individuals. Interested applicants should submit a Letter of Inquiry through the online application system.

The Alzheimer’s Association Research Fellowship for All (AARFA) Program aims to support early career researchers dedicated to advancing the understanding and treatment of Alzheimer’s and other dementias. By providing funding to postdoctoral researchers under established mentorship, the program fosters the development of independent scientists. It encourages applications from individuals in underrepresented groups, recognizing the value of diverse perspectives in scientific inquiry and clinical practice, ultimately contributing to the fight against dementia.

The Alzheimer’s Association Clinician Scientist Fellowship for All (AACSFA) aims to support the training of clinician scientists in Alzheimer’s and other dementias. This program encourages applications from individuals in underrepresented groups, emphasizing the value of diverse representation in clinical and scientific fields. The fellowship is designed for professionals with patient contact or diagnostic roles, fostering advancements in dementia research and care.

The Anne & Irving Brodsky Innovation Grant, offered by the Alzheimer's Foundation of America, provides $25,000 to support innovative programs that enhance the lives of individuals affected by Alzheimer's disease and related conditions. This grant is exclusively available to AFA nonprofit member organizations, with funding directed towards essential program expenses such as staff training, administrative costs, and necessary supplies. The initiative aims to foster advancements in care and support for families dealing with Alzheimer's.

The Project Lifesaver International Grant by the Alzheimer’s Foundation of America aims to fund programs that prevent wandering and enhance public safety for individuals with dementia-related illnesses. This grant supports public safety agencies that are members of AFA and Project Lifesaver International, focusing on essential training, supplies, and community outreach. Grants are awarded biannually, promoting better care and safety for individuals living with Alzheimer’s disease and related dementias.

The Milton & Phyllis Berg Family Respite Care Grants, offered by the Alzheimer’s Foundation of America, support member organizations in providing respite care scholarships to families affected by Alzheimer's. This initiative enhances the quality of life for both individuals and caregivers by promoting social engagement and offering essential breaks for caregivers. Grants are awarded biannually in memory of Barry E. Berg's parents, who faced Alzheimer's and caregiving challenges.

The Alzheimer’s Association and ASNR Imaging Research Grant focuses on advancing imaging research in Alzheimer’s and other neurodegenerative diseases. This partnership aims to support early-stage pilot projects that develop novel imaging tools and innovative data analysis methods. Up to three proposals will be funded, with each award capped at $200,000 for one year, promoting significant advancements in the field and enhancing research capabilities for better understanding of dementia.

The National Institute on Aging, in collaboration with the National Institute on Deafness and Other Communication Disorders, is announcing a Notice of Funding Opportunity (NOFO) aimed at exploring the link between olfactory decline and aging, Alzheimer's disease, and related dementias. This research could reveal olfactory dysfunction as a health indicator in older adults and identify new targets for therapeutic strategies. While applications are not currently being accepted, interested researchers are encouraged to prepare for future submissions.

The National Institute on Aging (NIA) is set to announce a funding opportunity for research on the cerebellum's role in cognitive and emotional functions during aging and Alzheimer's disease. This initiative emphasizes the need for studies that enhance understanding of cerebellar physiology and neuroanatomy in these contexts, welcoming diverse research approaches. Researchers are encouraged to prepare for this new opportunity to investigate potential interventions aimed at cognitive preservation and delaying Alzheimer's onset.

Margaret B. Moeller Memorial Fund for Alzheimer's Home Care Companions

Grants support families in the Boyertown Area School District with members who suffer from Alzheimer's disease or other types of dementia.

The Margaret B. Moeller Fund for Alzheimer's Home Care Companions provides grants for families in the Boyertown Area School District with individuals who suffer from Alzheimer's disease or other types of dementia to obtain the services of in-home care companions, aides or other providers of respite care. Grants generally pay for several days of care for a specified period of time. The fund was created to help families who are not eligible for any other form of reimbursement for such services. Decisions are generally made within 15 days of receiving a complete application, including the referral.

The National Institute on Aging (NIA) is set to release a Notice of Funding Opportunity (NOFO) aiming to stimulate research on Alzheimer's disease (AD) and related dementias (ADRD). This initiative focuses on validating novel drug targets and supports early-stage drug discovery efforts. The U01 activity code will be utilized, and while applications are not currently solicited, this notice allows potential applicants ample time to form collaborations and develop impactful projects in the field of AD/ADRD research.

The National Institute of Neurological Disorders and Stroke (NINDS) is launching a collaborative initiative aimed at exploring neurodegenerative mechanisms in Alzheimer’s disease-related dementias (ADRD). This program, termed 'Centers without Walls', encourages interdisciplinary teams to merge diverse expertise, utilizing cutting-edge technologies and clinical insights to uncover novel ADRD pathways. By fostering collaboration and data sharing, the initiative seeks to enhance understanding of ADRD complexities and support the development of innovative therapeutic strategies.

The National Institute of Neurological Disorders and Stroke (NINDS) aims to fund research on how environmental factors influence Alzheimer’s disease-related dementias (ADRD). This includes studying toxins, sleep patterns, and stress in relation to ADRD pathology and resilience. Applicants should explore synergistic effects of these factors and their impact on neurobiological mechanisms. Emphasis is placed on lifespan studies and health disparities. Collaboration among experts in exposomics, neuroscience, and community engagement is encouraged to advance understanding in this critical area.

The National Institute of Neurological Disorders and Stroke (NINDS) aims to support innovative research for validating therapeutic targets in Alzheimer's Disease-Related Dementias (ADRD). This initiative focuses on overcoming barriers in treatment development by ensuring well-validated targets linked to disease mechanisms. By employing a phased award mechanism, NINDS seeks to enhance the rigor of target validation, facilitating the transition from basic discoveries to clinical applications, ultimately accelerating the development of effective therapeutic strategies.

Health Services Research in Alzheimer’s Disease and Related Disorders (HSR-ADRD) Program

The HSR-ADRD program seeks to support research that strengthens dementia detection, diagnosis, and post-diagnostic care pathways along the care continuum. Projects may address a range of health services research questions, including, but not limited to, studies examining barriers and solutions to timely access, quality, and care coordination. By supporting rigorous and innovative research, this program aims to generate actionable evidence to improve person-centered, coordinated, and equitable brain health and dementia care.

Program overview

The program welcomes proposals that utilize rigorous methodologies to advance understanding and improvement of cognitive impairment, including MCI and Alzheimer’s disease and related dementias (AD/ADRD) detection, diagnosis, and post-diagnostic care.

This award is structured as an individual research grant, with funding administered through the recipient’s institution. Proposals should address one or more Areas of Focus. Areas of Focus represent high-priority research topics for which this program is actively seeking proposals and include: 

• The Value of Early Detection and Diagnosis: Studies should investigate outcomes associated with early detection and diagnosis on at least two levels of the dementia care ecosystem (i.e., individual/families, providers/clinicians, health systems/payers, and policy/society).
• Care Pathways for Individuals with MCI or Dementia: Studies should consider comorbidities and investigate how people are being screened and diagnosed in different settings, and the post-diagnosis pathways for care and treatment, including pharmacological and non-pharmacological interventions or combinations thereof.

Funding overview

• Each HSR-ADRD award is limited to a total of $250,000 U.S. (direct and indirect costs) for a duration of up to two years (awards should be a minimum one year).
• Indirect costs are capped at 10 percent of total direct costs and are inclusive of indirect costs for the implementing institution as well as for any subcontracts.

The NIH Blueprint for Neuroscience Research Network aims to enhance foundational research on human consciousness, addressing critical biomedical issues such as coma and dementia. By fostering a collaborative framework among 14 NIH institutes, the initiative seeks to improve diagnosis and treatment of neurological disorders through interdisciplinary approaches. Key objectives include detecting consciousness in minimally responsive patients, enhancing understanding of sleep disorders, and exploring new methodologies. This effort will ultimately strengthen U.S. leadership in neuroscience and improve patient outcomes.

The DoW Alzheimer’s Transforming Research Award supports innovative research aimed at reducing the risk and preventing Alzheimer’s disease and related dementias. It emphasizes projects that enhance understanding of risk factors and develop effective risk reduction strategies. Clinical research is permitted, but trials and animal studies are not. Collaboration and preliminary data are essential for proposal consideration, and an option for multiple principal investigators is available to foster partnerships.

The FY26 Alzheimer’s Research Program's Transforming Diagnosis Award (TrDA) promotes innovative research aimed at overcoming significant barriers to accurate diagnosis and monitoring of Alzheimer's disease. This award encourages community collaboration and requires preliminary data. It supports studies leveraging existing cohorts, especially those including individuals aged 65 and younger. The TrDA also offers a partnership option for multiple principal investigators, fostering collaborative research efforts while ensuring at least one independent investigator meets eligibility criteria.

The DoW Alzheimer’s Transforming Care Award aims to support innovative clinical research and trials enhancing dementia care for individuals with Alzheimer’s disease. This funding opportunity encourages collaborative partnerships and requires preliminary data, focusing on interventions that do not solely test pharmacological solutions. Community collaboration is essential, and studies leveraging existing cohorts, including those with younger participants, are encouraged. The award supports both new and existing partnerships among principal investigators.

The NIA Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) aims to create a secure, scalable cloud platform for genetic data related to Alzheimer’s disease. This initiative will enhance data accessibility, promote interoperability, and support rigorous research practices. By facilitating collaboration and providing robust analytical tools, the platform will maximize the scientific impact of AD/ADRD research, aligning with NIH goals for transparent and reproducible science, while addressing recommendations for broad access to high-value datasets.

The National Institute on Aging (NIA) is inviting applications for the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional). This initiative seeks to support pre-clinical and early-stage clinical development of innovative drug candidates aimed at preventing Alzheimer's disease or treating its symptoms. The program encourages collaboration among researchers and aims to enhance the therapeutic pipeline for AD through targeted approaches. This notice allows potential applicants time to prepare robust projects.